Trial reportJournal of neurology2011
Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial.
Trial report in Journal of neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Can Vitamin D Supplementation Prevent Bone Loss in Persons With MS? A Randomised, Placebo-controlled, Single-centre Study
The Effect of Vitamin D Substitution on Pancreatic Parenchyma and Development of Fibrosis After First Acute Alcoholic Pancreatitis: A Randomized Prospective Trial
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Role of vitamin D as adjuvant therapy on multiple sclerosis: an updated systematic review and meta-analysis of randomized controlled trials.European journal of medical research · 2025Pooled it
- Vitamin D for the management of multiple sclerosis.The Cochrane database of systematic reviews · 2018Pooled it
- Influence of Diet in Multiple Sclerosis: A Systematic Review.Advances in nutrition (Bethesda, Md.) · 2017Pooled it
- A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis.Neuroepidemiology · 2013Pooled it
- High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial.BMC neurology · 2017Trial
- Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis.Journal of neurology · 2015Trial
- What is needed to keep persons with multiple sclerosis vitamin D-sufficient throughout the year?Journal of neurology · 2013Trial
- Integrating Genetics and Environment to Find Causal Mechanisms for Multiple Sclerosis.European journal of immunology · 2026Review
- Bone Mineral Density Loss in Relapsing-remitting Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Matched Case-control Study.International journal of preventive medicine · 2026Article
- Short-Term Risk Factors for Bone Loss in Multiple Sclerosis: A Prospective Study and Literature Review.European journal of neurology · 2025Review
- The Effectiveness of Vitamin D Intake in Improving Symptoms and Relapses of Multiple Sclerosis: A Systematic Review.Cureus · 2024Review
- Review
- Prevalence of bone mineral density loss and potential risk factors for osteopenia and osteoporosis in rheumatic patients in China: logistic regression and random forest analysis.Annals of translational medicine · 2020Article
- High-Dose Vitamin D-Mediated Hypercalcemia as a Potential Risk Factor in Central Nervous System Demyelinating Disease.Frontiers in immunology · 2020Review
- Review
- Dietary Supplements on Controlling Multiple Sclerosis Symptoms and Relapses: Current Clinical Evidence and Future Perspectives.Medicines (Basel, Switzerland) · 2019Review
- Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration.Neuromolecular medicine · 2018Review
- Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease.Current osteoporosis reports · 2016Review
- Some recent advances in multiple sclerosis.Journal of neurology · 2016Review
- Vitamin D: link between osteoporosis, obesity, and diabetes?International journal of molecular sciences · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a possible cause of secondary osteoporosis. In this phase II trial we assessed whether a weekly dose of 20,000 IU vitamin D(3) prevents bone loss in ambulatory persons with MS age 18-50 years. ClinicalTrials.gov ID NCT00785473. All patients managed at the University Hospital of North Norway who fulfilled the main inclusion criteria were invited to participate in this double-blinded trial. Participants were randomised to receive 20,000 IU vitamin D(3) or placebo once a week and 500 mg calcium daily for 96 weeks. The primary outcome was the effect of the intervention on percentage change in bone mineral density (BMD) at the hip, the spine, and the ultradistal radius over the study period. Of 71 participants randomised, 68 completed. Mean serum 25-hydroxyvitamin D [25(OH)D] levels in the intervention group increased from 55 nmol/L at baseline to 123 nmol/L at week 96. After 96 weeks, percentage change in BMD did not differ between groups at any site. BMD decreased at the hip, by 1.4% in the placebo group (95% CI -2.3 to -0.4, SD 2.7, p = 0.006) and by 0.7% in the treatment group (-1.6 to 0.2, 2.7, p = 0.118), difference 0.7% (-1.9 to 0.7, p = 0.332). Findings were not altered by adjustment for sex or serum 25(OH)D. Supplementation with 20,000 IU vitamin D(3) a week did not prevent bone loss in this small population. Larger studies are warranted to assess the effect of vitamin D on bone health in persons with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.